Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP4K4 | O95819 | 3/20 | 0.51 |
| ▸ | JAK3 | P52333 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | PARP1 | P09874 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | EGFR | P00533 | 1/20 | 0.41 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.40 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27524704 | 0.92 | MAP4K4 (0.48) | MAP4K4JAK3ALDH1A1HTTMAPK1 | |
| SCHEMBL4422529 | 0.84 | JAK3 (0.42) | MAP4K4JAK3LMNA | |
| SCHEMBL5030719 | 0.83 | BRAF (0.51) | MAP4K4JAK3ALDH1A1HTTMAPK1 | |
| SCHEMBL4425074 | 0.82 | LHCGR (0.45) | MAP4K4 | |
| SCHEMBL6536790 | 0.79 | LHCGR (0.46) | MAP4K4JAK3ALDH1A1HTTMAPK1 | |
| SCHEMBL30673523 | 0.79 | LHCGR (0.64) | MAP4K4JAK3MAPK1 | |
| SCHEMBL5026884 | 0.79 | LHCGR (0.64) | MAP4K4JAK3MAPK1 | |
| SCHEMBL4432379 | 0.76 | LHCGR (0.43) | MAP4K4PARP1KDM4ESMN1; SMN2EGFR | |
| SCHEMBL5030680 | 0.76 | LHCGR (0.53) | MAP4K4ALDH1A1 | |
| SCHEMBL5026102 | 0.76 | LHCGR (0.53) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7618963-B2 | Bicyclic heteroaromatic compounds | N.V. ORGANON (NL) | 2009-11-17 | — | — | US | disclosed |
| US-20070197527-A1 | Bicyclic heteroaromatic compounds | N.V. ORGANON (NL) | 2007-08-23 | — | — | US | disclosed |
| US-7229990-B2 | Bicyclic heteroaromatic compounds | N.V. ORGANON (NL) | 2007-06-12 | — | — | US | disclosed |
| US-20030225113-A1 | Bicyclic heteroaromatic compounds | MERCK SHARP & DOHME B.V. (NL) | 2003-12-04 | — | — | US | disclosed |
| EP-1322651-A1 | BICYCLIC HETEROAROMATIC COMPOUNDS | Akzo Nobel N.V. (NL) | 2003-07-02 | — | — | EP | disclosed |
| WO-2002024703-A1 | BICYCLIC HETEROAROMATIC COMPOUNDS | AKZO NOBEL N.V. (NL) | 2002-03-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030225113-A1 | Bicyclic heteroaromatic compounds | NR5A1, CYP19A1, FSHR | MAP4K4 4407/4885JAK3 3002/4885ALDH1A1 1372/4885 |
| US-20070197527-A1 | Bicyclic heteroaromatic compounds | NR5A1, CYP19A1, FSHR | MAP4K4 4372/4885JAK3 2306/4885ALDH1A1 1340/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.